Silexion Lays Out SIL204 Timeline: Phase 2/3 Underway, Early Data on Deck for Q4 2026
SLXN sits 18% above its 52-week low of $1.5 on light trading volume (0.1× avg).
Summary
Silexion Therapeutics released an updated corporate presentation detailing the clinical timeline for SIL204, its lead siRNA candidate for KRAS-driven cancers. The Phase 2/3 trial is underway, and early human data are expected in Q4 2026.
Key Events · Product Development and Regulatory · SLXN
-
Phase 2/3 Trial Initiated July 2026
Dosing began in July 2026 for the SIL204 Phase 2/3 trial in locally advanced pancreatic cancer (LAPC), following regulatory green lights in Israel and Germany. The study combines intratumoral and systemic SIL204 with standard-of-care chemotherapy.
-
Early Human Data Expected Q4 2026
A near-term readout is on the horizon: early human data, including ctDNA biomarker results, are expected in Q4 2026 and could offer initial efficacy signals.
-
Preclinical Data Supports Dual-Delivery Approach
Fresh preclinical data show SIL204 silences KRAS RNA and protein, inhibits growth of multiple KRAS-mutant human tumor cell lines at sub-nanomolar concentrations, and synergizes with chemotherapy. Toxicology studies found no systemic toxicity or organ damage.
-
Regulatory and Expansion Milestones
An IND application is planned for Q1 2027 to bring the trial to the U.S. and EU. Phase 2 expansion is set to begin in Q1 2027, with Phase 3 confirmatory initiation slated for Q3 2030.
Analysis · SLXN · Life Sciences
An updated corporate presentation from Silexion Therapeutics maps out the clinical path for SIL204, a first-in-class siRNA aimed at KRAS-driven cancers. Dosing in the Phase 2/3 trial for locally advanced pancreatic cancer began in July 2026, and early human data are expected in Q4 2026 — a near-term catalyst that could validate the dual-delivery strategy targeting both primary tumors and micrometastases. The deck also features new preclinical evidence: SIL204 silences KRAS RNA and protein, suppresses tumor growth across multiple KRAS mutations, and shows a favorable safety profile. With a going-concern warning and a recent reverse split to maintain Nasdaq listing as the backdrop, this update delivers a concrete timeline and scientific rationale that may reshape how investors view the company's prospects.
At the time of this filing, SLXN was trading at $1.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2M. The 52-week trading range was $1.50 to $86.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.